Shenzhen Salubris Pharmaceuticals Co., Ltd
http://www.salubris.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shenzhen Salubris Pharmaceuticals Co., Ltd
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
'Buy China' In Procurement Schemes - Should You Worry?
A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.
China Reveals Winners Of Bidding War
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
Ready, Set, Lowest: Who Won China’s Latest Drug Bidding War?
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Services
- Other Names / Subsidiaries
-
- Salubris Biotherapeutics Inc., Splendris Pharmaceuticals GmbH, Genekey Biotech (Chengdu) Co., Ltd., Genemen Biotech (Suzhou) Co., Ltd., Alain Medical (Beijing) Co., Ltd., Shenzhen Keyidun Biomedical Technology Co., Ltd.